Saturday August 24, 2019 19:44

Heathcare Press Release : 06 Feb 2019

BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Heathcare—06 Feb 19

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has priced an underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), each representing one

Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Heathcare—06 Feb 19

- Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers - Merck will receive an upfront payment of EUR300 million and is eligible for